IGF1 and prostate cancer: Acromegaly patients with systemically high growth hormone (GH) and IGF-1 levels also have significantly higher incidence of prostate cancer and risk of prostate cancer-related mortality (HR = 1.33 and 1.44, respectively), suggesting that IGF-1 has a positive effect on prostate cancer development and progression [66].